Copyright
©The Author(s) 2015.
World J Gastroenterol. Dec 14, 2015; 21(46): 13004-13019
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13004
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13004
Figure 7 Cell viability analysis (MTT).
Viability was analyzed in control cells, cells treated with gemcitabine (GEM) IC50, siHUR alone, and GEM IC50 treatment after HuR siRNA. Transfection with HuR siRNA had little or no effect on cell viability, while HuR silencing dramatically increased response of pancreatic cancer cells to the GEM treatment. HuR: Human antigen R.
- Citation: Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol 2015; 21(46): 13004-13019
- URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13004.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13004